Increased 18 F-FDG Avidity on PET/CT During Treatment for Rhabdomyosarcoma Confirmed to Be Mature Rhabdomyoblasts.

J Pediatr Hematol OncolJul 2, 2026 (epub)
Case ReportOncology (Medical)Pediatrics

Nicole Baca, Fataneh Majlessipour, Christopher T Watterson et al.

✦ AI-curated · Sources linked

Case in brief

An adolescent with metastatic fusion-positive rhabdomyosarcoma exhibited a new 18 F-FDG-PET avid focus in the radiation field during systemic chemotherapy, raising concerns for disease progression. Subsequent resection of the lesion revealed it to be mature rhabdomyoblasts. The patient has remained in remission for 26 months post-resection and 20 months after completing treatment.

Diagnostic / clinical pearl

Increased 18 F-FDG avidity during treatment may not always indicate disease progression, as it can represent mature rhabdomyoblasts in rhabdomyosarcoma.

Source

PubMed · PMID 42391102

Published in J Pediatr Hematol Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.